GSK3B and neoplasm: In vivo, tideglusib had no effect on tumor progression or myodifferentiation, although pharmacodynamic examination showed efficient reduction in GSK3β mediated phosphorylation of β-catenin at Ser33/37 and Thr41 and consequent stabilization of β-catenin [17].